(Reuters) - Moderna Inc has begun dosing patients in a mid-to-late stage study of its COVID-19 vaccine, mRNA-1273, in children aged six months to less than 12 years, the company said on Tuesday.
Germany, France and Italy temporarily suspended the use of AstraZeneca’s Covid-19 vaccine on Monday, joining a growing list of nations that paused use of the vaccine in recent days over concerns that it might be tied to blood clots.
Leading public health agencies, including the World Health Organization, say that millions of people have received the vaccine without experiencing blood clotting issues, and they caution that experts have not found a causative link between the vaccine and the conditions. The company has also defended the vaccine as safe, amid the flurry of suspensions.
Facebook, which has been criticized by lawmakers and researchers for allowing vaccine misinformation to spread on its platforms, said on Monday it has started adding labels to posts that discuss the safety of the shots and will soon label all posts about the vaccines.
VIENNA (Reuters) - The European Commission on Saturday defended its policy of distributing COVID-19 vaccines evenly in the bloc after Austria and five other member states complained that doses were not allocated equally.
Recent Comments